Author

Nathan Constantine-Cook

LONG-TERM OUTCOMES FOLLOWING A SWITCH FROM ORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5 (IMRALDI) IN IBD
LONG-TERM OUTCOMES FOLLOWING A SWITCH FROM ORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5 (IMRALDI) IN IBD

Nathan Constantine-Cook  et al.

Item 1 - 1 / 1
1